Skip to main content

Table 3 Comparison of all lupus nephritis treatments for a composite of renal relapse or renal flare

From: Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis

Treatment

Reference

Odds ratio (95 % CrI)

Relative risk (95 % CrI)

Risk difference % (95 % Crl)

AZA

PRED

0.33 (0.08, 1.23)

0.50 (0.17, 1.12)

−0.24 (−0.47, 0.05)

MMF

 

0.17 (0.04, 0.67)

0.29 (0.09, 0.78)

−0.34 (−0.53, −0.09)

CYC

 

0.18 (0.05, 0.58)

0.31 (0.11, 0.71)

−0.33 (−0.51, −0.12)

CSA

 

0.24 (0.03, 1.60)

0.39 (0.07, 1.26)

−0.29 (−0.52, 0.11)

CYC + AZA

 

0.32 (0.05, 1.67)

0.48 (0.10, 1.29)

−0.25 (−0.50, 0.12)

MMF-AZA

 

0.41 (0.03, 5.46)

0.58 (0.07, 1.83)

−0.20 (−0.51, 0.36)

MMF

AZA

0.51 (0.32, 0.87)

0.59 (0.38, 0.90)

−0.10 (−0.20, −0.02)

CYC

 

0.55 (0.24, 1.26)

0.62 (0.32, 1.21)

−0.09 (−0.26 0.03)

CSA

 

0.74 (0.18, 2.95)

0.80 (0.23, 2.01)

−0.04 (−0.23, 0.23)

CYC + AZA

 

0.95 (0.27, 3.09)

0.96 (0.34, 2.11)

−0.01 (−0.19, 0.24)

MMF-AZA

 

1.23 (0.14, 12.15)

1.16 (0.19, 3.76)

0.04 (−0.25, 0.53)

CYC

MMF

1.06 (0.44, 2.58)

1.05 (0.51, 2.29)

0.01 (−0.13, 0.12)

CSA

 

1.43 (0.32, 6.17)

1.33 (0.36, 3.81)

0.04 (−0.12, 0.35)

CYC + AZA

 

1.84 (0.51, 6.00)

1.62 (0.56, 3.85)

0.08 (−0.07, 0.35)

MMF-AZA

 

2.39 (0.27, 23.30)

1.94 (0.31, 6.94)

0.13 (−0.12, 0.63)

CSA

CYC

1.35 (0.27, 6.52)

1.27 (0.31, 3.86)

0.04 (−0.14, 0.37)

CYC + AZA

 

1.72 (0.44, 6.37)

1.53 (0.49, 3.83)

0.08 (−0.09, 0.3)

MMF-AZA

 

2.24 (0.24, 23.15)

1.85 (0.28, 6.46)

0.13 (−0.13, 0.63)

CYC + AZA

CSA

1.27 (0.20, 8.09)

1.20 (0.30, 5.35)

0.03 (−0.29, 0.35)

MMF-AZA

 

1.67 (0.13, 25.89)

1.43 (0.19, 8.68)

0.08 (−0.31, 0.62)

MMF-AZA

CYC + AZA

1.30 (0.22, 9.13)

1.20 (0.28, 3.68)

0.04 (−0.01, 0.46)

Random-effects model

Residual deviance

32.06 vs. 28 data points

  
 

Deviance information criteria

146.869

  

Fixed-effects model

Residual deviance

34.31 vs. 28 data points

  
 

Deviance information criteria

147.018

  
  1. Based on 13 RCTs with 1108 patients: 11 two-arm trials and two three-arm trials
  2. Significant odds ratios are in italics
  3. For absolute rates for events used for calculation of risk difference, please see Appendix 6
  4. OR odds ratio, RR relative risk, RD risk difference, CrI credible interval, CYC cyclophosphamide, MMF mycophenolate mofetil, CSA cyclosporine, TAC tacrolimus, LEF leflunomide, PRED prednisone, prednisolone or methylprednisolone, AZA azathioprine, RTX rituximab
  5. CYC + AZA CYC with AZA, MMF-AZA MMF followed by AZA
  6. Merged doses for PRED and CYC and comparing only between treatments. We did not lose any study, but it is a limitation of this analysis
Back to article page

Systematic Reviews

ISSN: 2046-4053